Version 1.0 — Published September 2026
Quick Answer
Massive hemoptysis is a repeatedly-tested NEET PG emergency — the definition (greater than 200 mL single expectoration, greater than 600 mL in 24 hours, or hemodynamic instability), asphyxiation as the primary mode of death, the aetiologic profile in India (post-TB, aspergilloma, bronchiectasis, malignancy), bleeding-side-down positioning, tranexamic acid, bronchoscopy, and bronchial artery embolization (BAE) recur every cycle. A 42-year-old smoker with previous pulmonary TB now presenting with 550 mL blood in 60 minutes, HR 130, BP 105/70, SpO2 90 percent, and a CT showing an intracavitary fungus ball in the right upper lobe with an air-crescent sign needs the following 8-step workflow:
- Recognise massive hemoptysis — volume, hemodynamic effect, respiratory compromise.
- Airway first — position bleeding-side DOWN (right lateral decubitus); high-flow O2; prepare for large-bore intubation.
- IV access and resuscitation — two 16G lines, crystalloid, type and crossmatch 4 units PRBC.
- Tranexamic acid 1 g IV over 10 min then 1 g every 8 h; correct coagulopathy (vitamin K, FFP, platelets to greater than 50,000).
- Antitussive — codeine or morphine to reduce cough-driven re-bleeding, avoiding oversedation.
- Rigid bronchoscopy for localisation and tamponade (cold saline lavage, topical adrenaline, thrombin, balloon blocker).
- Bronchial artery embolization (BAE) — first-line definitive intervention; 85-95 percent acute control, 20-30 percent 1-year recurrence.
- Definitive surgery (lobectomy/segmentectomy) for BAE failure, aspergilloma, AVM, or localised malignancy.
The case
A 42-year-old male truck driver from rural Maharashtra presents to the emergency department at 04:20 with sudden coughing up of frank red blood — an estimated 400 mL in the last hour at home, and an additional 150 mL witnessed on arrival to the resuscitation bay. He is a chronic bidi smoker (25 pack-years), was diagnosed with sputum-positive pulmonary TB 10 years ago and completed a full 6-month course of DOTS-based ATT under RNTCP with documented microbiological cure. Over the last 6 months he reports gradual weight loss (3 kg), intermittent low-grade evening rise of temperature, streaky hemoptysis (small quantities two to three times a week), and reduced exercise tolerance. He has not sought care until now because the previous hemoptysis episodes were minor.
He has never taken azole antifungals. He has no known drug allergies, is on no regular medications, denies fever, chest pain, or trauma. There is no family history of TB in the last 5 years.
Examination on arrival — patient sitting bolt upright, distressed, actively spitting bright red blood into a bowl at the bedside. Temperature 37.2 degrees C, pulse 130/min regular thready, respiratory rate 28, BP 105/70, SpO2 90 percent on 4 L nasal cannula. Capillary refill 3 seconds.
Airway — patent, patient speaking in phrases, no stridor; blood streaking the lips and chin.
Breathing — accessory muscle use, chest expansion reduced on the RIGHT, dull percussion right upper zone, coarse crackles and rhonchi bilaterally, more marked on the right upper zone, no wheeze, no pleural rub. Old healed clavicular scars from prior BCG.
Circulation — thready peripheral pulse, capillary refill 3 seconds; no peripheral oedema; no raised JVP.
Abdomen — soft, non-tender, no organomegaly.
CNS — alert, oriented; anxious.
The ER registrar recognises this as massive hemoptysis (over 500 mL in one hour, with hemodynamic strain and respiratory compromise). The patient is immediately positioned right lateral decubitus (bleeding side down) to protect the non-bleeding left lung, oxygen is escalated to a non-rebreather at 15 L, two large-bore IVs are established, blood is drawn for CBC, coagulation, and cross-match, tranexamic acid is prepared, and cardiothoracic surgery and interventional radiology are called simultaneously.
The three time-critical principles
Principle 1 — Airway protection before hemostasis. Patients with massive hemoptysis die of asphyxiation from blood filling the tracheobronchial tree, not from exsanguination. Bleeding-side-down positioning uses gravity to protect the good lung. Early intubation with a large-bore ETT (8.0 mm ID or larger) allows adequate suctioning. Consider a double-lumen tube or endobronchial blocker for definitive isolation.
Principle 2 — Bronchial artery embolization is the definitive intervention for most cases. The bleeding source is bronchial arterial (systemic, high pressure) in 90 percent of cases. BAE controls acute bleeding in 85-95 percent, has a favourable safety profile in experienced hands, and buys time for definitive treatment of the underlying cause. Surgery is reserved for BAE failure or specific indications (aspergilloma with recurrent bleed, AVM, localised malignancy).
Principle 3 — Do not overlook aspergilloma in a post-TB patient. In India, up to a quarter of patients with healed TB cavities develop aspergilloma, and up to 90 percent of aspergillomas produce hemoptysis. A CT thorax showing an intracavitary rounded mass with an air-crescent sign is diagnostic. Serum Aspergillus IgG confirms. Definitive management is BAE for acute control followed by surgical resection once stable.
Investigations
Bedside (within 15 minutes)
- Portable chest X-ray — right upper lobe cavitary lesion (old fibrocavitary changes), a rounded intracavitary opacity, adjacent fibrotic infiltrate; no new consolidation of the left lung; heart size normal; no widened mediastinum; no pneumothorax.
- Bedside arterial blood gas — pH 7.34, pCO2 34, pO2 60 (on 4 L nasal cannula), lactate 2.4 mmol/L — mild hypoxaemia; no severe acidosis yet.
- ECG — sinus tachycardia at 128; no ischaemic changes.
Laboratory
- CBC — Hb 10.2 g/dL (baseline 12 g/dL 6 months ago, so acute drop from bleeding), WBC 9,500, platelets 200,000.
- Coagulation — INR 1.1, aPTT normal, fibrinogen normal.
- Urea, creatinine, electrolytes — creatinine 1.0, Na 136, K 3.9.
- LFTs — normal.
- Type and crossmatch 4 units PRBC — send urgently.
- Sputum smear for AFB, GeneXpert MTB/RIF, mycobacterial culture — sent to rule out active TB reactivation (essential — MDR-TB in a treated patient changes ATT regimen).
- Serum Aspergillus IgG (precipitins), galactomannan — sent given cavitary lung disease.
- BNP — precautionary if cardiac involvement suspected.
Definitive imaging
- CT thorax with contrast (multiplanar reconstruction) — right upper lobe fibrocavitary changes from prior TB with a 4 cm intracavitary rounded mass and an air-crescent sign consistent with a mycetoma (aspergilloma). Hypertrophied tortuous bronchial arteries with peribronchial neovascularity. A 6 mm outpouching from a segmental branch of the right pulmonary artery within the cavity wall suggestive of a Rasmussen pseudoaneurysm. Left lung clear.
- CT pulmonary angiography if PE suspected — not indicated here given the classical CT findings.
Interpretation — massive hemoptysis in a post-TB patient from a right upper lobe aspergilloma with a likely Rasmussen aneurysm; bronchial artery embolization is the immediate definitive intervention, with elective surgical resection of the aspergilloma after stabilisation.
Diagnosis
Massive hemoptysis (approximately 550 mL in 60 minutes with hemodynamic strain and respiratory compromise) — right upper lobe aspergilloma in a healed TB cavity with a probable Rasmussen pseudoaneurysm as the bleeding source (CT air-crescent sign, hypertrophied bronchial arteries, pulmonary artery outpouching, positive Aspergillus IgG expected) — for airway control with right lateral decubitus positioning and large-bore intubation as needed, tranexamic acid 1 g IV over 10 min then 1 g every 8 h, correction of any coagulopathy, rigid bronchoscopy for localisation and tamponade, urgent bronchial artery embolization by interventional radiology, then elective right upper lobectomy after stabilisation and pulmonary function assessment. Simultaneous smear, GeneXpert and culture to exclude active TB reactivation and MDR-TB.
Management — first ten minutes, definitive intervention, and post-procedure
First ten minutes — airway and resuscitation
- Position bleeding-side DOWN — right lateral decubitus in this patient (bleeding source is right upper lobe cavity) — uses gravity to protect the left lung from aspiration and preserves ventilation on the good side.
- High-flow oxygen — 15 L via non-rebreather to keep SpO2 above 92 percent.
- Two large-bore (16G) IV access lines — one for fluids and blood, one for drugs.
- Crystalloid bolus 500-1000 mL while cross-matched blood is awaited; do not over-resuscitate before hemostasis (permissive hypotension in surgical bleeding is acceptable).
- Cross-match 4 units PRBC, order 4 units FFP, order platelets if count under 50,000 with active bleed or under 100,000 with severe bleed.
- Tranexamic acid 1 g IV over 10 minutes, then 1 g every 8 hours; consider nebulised tranexamic acid 500 mg in 5 mL saline every 6-8 hours as adjunct.
- Correct any coagulopathy — vitamin K 10 mg IV, FFP if INR greater than 1.5, platelets to target.
- Antitussive — codeine 30 mg PO or morphine 2-5 mg IV to suppress cough-driven re-bleeding, titrated to avoid oversedation and airway compromise.
- Early intubation with a large-bore (8.0 mm ID or larger) ETT if hypoxaemia worsens or airway soiling threatens; awake fibreoptic intubation preferred if time allows. Consider double-lumen tube or endobronchial blocker for definitive isolation of the bleeding lung.
- Call cardiothoracic surgery and interventional radiology — the two decision-makers for definitive intervention.
Definitive intervention — bronchial artery embolization
- Rigid bronchoscopy first in most protocols — for localisation, aspiration of clots, and temporising haemostasis via cold saline lavage, topical adrenaline 1:20,000, topical thrombin, argon plasma coagulation, or endobronchial balloon (Fogarty catheter or bronchial blocker) tamponade of the bleeding segmental bronchus.
- Bronchial artery embolization (BAE) by interventional radiology — femoral arterial access, selective angiography of the right bronchial artery (and intercostobronchial trunk), identification of the bleeding vessel or pathological neovascular blush, superselective catheterisation, and embolization with polyvinyl alcohol particles (300-500 microns), gelfoam, or coils.
- Success rate 85-95 percent for acute control; 20-30 percent recurrence within 1 year (amenable to repeat BAE).
- Key complication to avoid — inadvertent embolization of the anterior spinal artery arising from the intercostobronchial trunk causing transverse myelitis — mitigated by preserving flow and using appropriate particle size.
- Other complications — chest pain (common, self-limiting), non-target embolization (oesophagus, systemic), femoral haematoma.
Definitive treatment by aetiology
- Aspergilloma (our patient) — BAE for acute control; right upper lobectomy as elective definitive surgery after stabilisation, adequate pulmonary function (predicted post-op FEV1 greater than 0.8 L or greater than 40 percent predicted), and nutritional optimisation. Oral itraconazole 200 mg twice daily or voriconazole 200 mg twice daily may reduce fungal burden but has limited role in acute hemoptysis.
- Active pulmonary TB (excluded by GeneXpert here) — resume 4-drug ATT (isoniazid, rifampicin, pyrazinamide, ethambutol) after acute bleeding controlled; escalate to MDR-TB regimen (bedaquiline, linezolid, levofloxacin, clofazimine, cycloserine) if resistance found.
- Bronchiectasis — airway clearance (postural drainage, chest physiotherapy, mucolytics), inhaled bronchodilators, macrolide prophylaxis (azithromycin) in select cases, treat exacerbations with antibiotics, elective resection of localised disease.
- Bronchogenic carcinoma — bronchoscopy biopsy after stabilisation, oncology referral for definitive staging and treatment (surgery, chemoradiation, immunotherapy).
- AVM — embolization or surgical resection.
- PE with infarction — anticoagulation once bleeding excluded or controlled (careful risk-benefit).
- Vasculitis — immunosuppression (steroids, cyclophosphamide, rituximab).
Post-procedure
- ICU admission for 24-48 hours of close monitoring.
- Serial haemoglobin and hemodynamic monitoring.
- Repeat CT thorax at 24-48 hours to assess for any collection.
- Bronchoscopy for airway clearance if secretions or clots retained.
- Pulmonary function tests and cardiac evaluation before elective surgery.
- Nutritional and rehabilitation support — many post-TB patients are malnourished.
Complications
Acute
- Death from asphyxiation — the primary mode of death in unmanaged massive hemoptysis.
- Aspiration pneumonia on the non-bleeding lung.
- Hemorrhagic shock — less common than asphyxiation but real; guides transfusion.
- Airway obstruction from clot — needs bronchoscopic clearance.
- BAE-related transverse myelitis — the feared complication of anterior spinal artery embolization.
Subacute
- Rebleeding — 20-30 percent within 1 year after BAE; amenable to repeat BAE.
- Post-embolization syndrome — chest pain, low-grade fever, malaise.
- Post-obstructive pneumonia distal to embolized segment.
Long-term
- Loss of pulmonary function proportional to embolized or resected lung.
- Chronic respiratory failure — cor pulmonale — post-TB structural lung disease burden.
- Recurrence of aspergilloma in a re-cavitary lung — needs long-term surveillance.
India-specific context
- TB burden — India carries roughly a quarter of the global TB burden. Post-TB structural lung disease (cavities, bronchiectasis, aspergilloma, chronic aspergillosis) is a large silent population; a treated-TB patient has a lifetime risk of hemoptysis around 10-20 percent.
- RNTCP/NTEP surveillance — every hemoptysis case with cavitary lung disease should be screened for TB reactivation and MDR-TB via GeneXpert MTB/RIF before restarting or modifying ATT.
- BAE access — restricted to tertiary and select secondary interventional-radiology-capable centres; hub-and-spoke transfer while temporising with airway control, tranexamic acid, and bronchoscopy is a common Indian scenario.
- PMJAY tertiary respiratory coverage — covers many of the diagnostic and interventional procedures; still, financial and geographic access is uneven.
- Air travel restriction — advise against commercial air travel for 4-6 weeks post-massive hemoptysis; pressure changes can precipitate re-bleeding.
- Bidi smoking and rural biomass exposure — additive risk factors for bronchiectasis, malignancy, and post-TB parenchymal damage.
How NEET PG tests massive hemoptysis
Pattern 1 — Definition question: Massive hemoptysis threshold? Greater than 200 mL single expectoration OR greater than 600 mL in 24 hours OR hemodynamic instability.
Pattern 2 — Mode of death: Primary cause of death? Asphyxiation, not exsanguination.
Pattern 3 — Positioning question: Immediate positioning? Bleeding-side DOWN (lateral decubitus) to protect the good lung.
Pattern 4 — Bleeding source anatomy: Source of bleeding in most cases? Bronchial arteries (systemic, high pressure) in 90 percent; pulmonary arteries in 10 percent (Rasmussen aneurysm classical).
Pattern 5 — Definitive intervention: First-line definitive intervention? Bronchial artery embolization (BAE) — 85-95 percent acute success, 20-30 percent recurrence.
Pattern 6 — Feared BAE complication: Transverse myelitis from inadvertent anterior spinal artery embolization arising from the intercostobronchial trunk.
Pattern 7 — Adjunct question: Tranexamic acid dose? 1 g IV over 10 min then 1 g every 8 h; nebulised route 500 mg in 5 mL every 6-8 h emerging.
Pattern 8 — Aspergilloma sign: CT sign? Air-crescent sign (halo of air around the mycetoma in a preformed cavity).
Pattern 9 — Rasmussen aneurysm: Definition? Pseudoaneurysm of a pulmonary artery branch traversing a tuberculous cavity.
Pattern 10 — Bronchoscopy choice: Rigid vs flexible? Rigid preferred in massive hemoptysis for wider suction and tool passage; flexible acceptable for localisation if rigid unavailable.
Key takeaways
- Massive hemoptysis is defined by volume (over 200 mL single, over 600 mL in 24 h) or hemodynamic effect.
- Death is by asphyxiation not exsanguination — airway before hemostasis.
- Position bleeding-side DOWN in lateral decubitus.
- Intubate early with a large-bore ETT (8.0 mm or larger).
- Bronchial arteries supply 90 percent of the bleeding; pulmonary arteries 10 percent.
- Bronchial artery embolization is first-line definitive intervention (85-95 percent acute success).
- Feared complication of BAE — transverse myelitis from anterior spinal artery embolization.
- Tranexamic acid 1 g IV then 1 g every 8 h; correct coagulopathy.
- Rigid bronchoscopy preferred over flexible in massive bleeding.
- India — always exclude active TB and MDR-TB with GeneXpert; consider aspergilloma in every post-TB patient with cavitary disease.
Frequently Asked Questions
What is the definition of massive hemoptysis and why is asphyxiation the primary mode of death?
Massive hemoptysis is variably defined but accepted working thresholds are greater than 200 mL in a single expectoration, greater than 600 mL over 24 hours, or any volume causing hemodynamic instability, respiratory failure, or airway obstruction. The volume needed to fill the anatomic dead space of the tracheobronchial tree (roughly 150 mL in the adult) is enough to cause fatal asphyxiation before circulatory collapse — patients drown in their own blood before they exsanguinate, so airway protection and bleeding-side-down positioning take priority over transfusion. Mortality in unmanaged massive hemoptysis is 30-50 percent; with early airway control and definitive intervention (BAE or surgery), mortality falls below 10 percent. The blood supply of the tracheobronchial tree comes from the bronchial arteries (systemic, high pressure) in 90 percent of massive hemoptysis, and from the pulmonary arteries (low pressure) in only 10 percent (Rasmussen aneurysm in a TB cavity is the classical example).
What are the commonest causes of massive hemoptysis in the Indian setting and how do they differ from Western series?
In India, tuberculosis and post-TB sequelae dominate. Active pulmonary TB, bronchiectasis from prior TB, aspergilloma (a fungus ball colonising a healed TB cavity, seen in 15-25 percent of post-TB cavitary lung disease), and Rasmussen aneurysm together account for 40-60 percent of massive hemoptysis in Indian series. Bronchiectasis of any cause accounts for another 20-30 percent. Bronchogenic carcinoma accounts for 10-20 percent and is rising with the smoking and air-pollution burden. Less common causes are pulmonary embolism with infarction, arteriovenous malformation, coagulopathy, cardiovascular disease (mitral stenosis, severe pulmonary hypertension), vasculitis (Goodpasture, GPA, EGPA), iatrogenic, and trauma. In contrast, Western series show a much larger share for bronchogenic carcinoma and bronchiectasis, with TB-related causes much less common. NEET PG typically anchors the vignette on a post-TB patient with cavitary lung disease and a fungus ball — the answer is aspergilloma with likely Rasmussen aneurysm.
What is the immediate airway and positioning approach in massive hemoptysis?
Airway management has three time-critical priorities. First, position the patient bleeding-side DOWN in the lateral decubitus position — uses gravity to protect the non-bleeding lung from aspiration and preserves ventilation on the good side. Second, high-flow oxygen 100 percent via non-rebreather to maintain SpO2 above 92 percent, and prepare for early intubation with a large-bore endotracheal tube (8.0 mm ID or larger) to allow adequate suctioning. A smaller tube may permit ventilation but will not permit therapeutic bronchoscopy. Third, consider a double-lumen ETT or single-lumen ETT plus endobronchial blocker to isolate the bleeding lung — the choice depends on operator experience and urgency. Awake fibreoptic intubation is ideal when time allows because it preserves spontaneous ventilation and lets the operator see the source of bleeding during placement. Avoid nasal intubation and supraglottic devices. Once intubated, sedate and paralyse; ventilate with low tidal volumes and PEEP; suction repeatedly.
What are the roles of tranexamic acid, bronchoscopy and bronchial artery embolization in definitive management?
After airway control, three interventions form the definitive management stack. Tranexamic acid — an antifibrinolytic; dose 1 g IV over 10 minutes then 1 g every 8 hours; alternative nebulised route 500 mg in 5 mL saline every 6-8 hours. Correct any coagulopathy or platelet count under 50,000 with FFP and platelet transfusions. Bronchoscopy — rigid preferred for massive hemoptysis because it provides a wider suction channel and lets the operator pass haemostatic tools; flexible acceptable when rigid unavailable and essential for localising the bleeding source. Interventions include cold saline lavage, topical adrenaline, topical thrombin, argon plasma coagulation, endobronchial balloon tamponade, and endobronchial stenting. Bronchial artery embolization (BAE) — the first-line definitive intervention. IR accesses the bronchial artery via femoral approach, identifies the bleeding vessel, and embolises with polyvinyl alcohol particles, gelfoam, or coils. Success 85-95 percent for acute control, 20-30 percent recurrence within 1 year. Feared complication — transverse myelitis from inadvertent spinal artery embolization. Surgery reserved for BAE failure, aspergilloma with recurrent bleed, AVM, and bronchogenic carcinoma.
How is aspergilloma diagnosed and managed and what specific role does BAE play for aspergilloma-related hemoptysis?
Aspergilloma is a fungus ball of Aspergillus fumigatus growing within a preformed pulmonary cavity, most commonly a healed post-TB cavity. Classical presentation is hemoptysis (60-90 percent of patients) in a patient with prior cavitary lung disease. Diagnosis is by CT thorax (a mobile intracavitary rounded mass with an air-crescent sign; typically upper lobe cavity), positive serum Aspergillus IgG or precipitins, and sputum culture. Workup includes chest CT with contrast to identify hypertrophied bronchial arteries, pulmonary function tests, and echocardiogram. Management stratified — simple aspergilloma with no or mild hemoptysis: observation; aspergilloma with recurrent or massive hemoptysis: BAE for acute control (highly effective because the pathological neovascularity from hypertrophied bronchial arteries and Rasmussen-like erosions is the bleeding source), followed by definitive surgical resection once stable and pulmonary function permits. Antifungal therapy — oral itraconazole or voriconazole may reduce fungal burden but has limited role in acute hemoptysis and does not eliminate the mechanical mass.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: September 2026
